Formulation, release characteristics and bioavailability study of oral monolithic matrix tablets containing carbamazepine

AAPS PharmSciTech

Volumn 9, Issue 3, 2008, Pages 931-938

  Barakat, Nahla S ^a   Elbagory, Ibrahim M ^a   Almurshedi, Alanood S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Bioavailability study; Carbamazepine; Controlled release matrix; In vitro in vivo correlation

Indexed keywords

CARBAMAZEPINE; CROSCARMELLOSE SODIUM; GLYCEROL BEHENATE; HYDROXYPROPYLMETHYLCELLULOSE; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG GRANULATION; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MATRIX TABLET; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; SINGLE DRUG DOSE; TABLET COMPRESSION; TABLET FORMULATION; TABLET PROPERTY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOGS; HYDROPHOBICITY; MALE; MODELS, CHEMICAL; TABLETS;

EID: 57149122878     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-008-9108-y     Document Type: Article

References (28)

1. J. R. Cardinal. Matrix systems, In R. S. Langer, and D. I. Wise (eds.), Medical Applications of Controlled Releas. Vol I, Classes of Systems, CRC Press, Boca Raton, FL, USA, 1984, pp. 41-67.
2. M. Stuchlík, and S. Žák. Lipid-based vehicle for oral drug delivery. Biomed Papers. 145:17-26 (2001).
3. D. Saraiya, and S. Bolton. The use of PrecirolÒ to prepare sustained release tablets of theophylline and quinidine gluconate. Drug Dev Ind Pharm. 16:1963-1969 (1990).
4. N. S. Barakat. Formulation and evaluation of some extended-release drugs, Ph.D. dissertation, Alexandria University, College of Pharmacy, Alexandria, Egypt. 1996.
5. I. Katzhendler, K. Mäder, and M. Friedman. Structure and hydration properties of hydroxypropylmethylcellulose matrices containing naproxen and naproxen sodium. Int J Pharm. 200:161-179 (2000).
6. F. Lotfipour, A. Nokhodchi, M. Saeedi, S. Norouzi-Sani, J. Sharbafi, and M. R. Siahi-Shadbad. The effect of hydrophilic and lipophilic polymers and fillers on the release rate of atenolol from HPMC matrices. IL Farmaco. 59:819-825 (2004).
7. S. Malamataris, and D. Ganderton. Sustained release from matrix system comprising hydrophobic and hydrophilic (gel-forming) parts. Int.J Pharm. 70:69-75 (1991).
8. B. F. D. Bourgeois, and N. Wad. Individual and combined epileptic and neurotoxic activity of carbamazepine and carbamazepine-10, 11-epoxide in mice. J Pharmacol. Exp Ther. 231:411-415 (1984).
9. E. Perrucca, and A. Richens. Clinical pharmacokinetics of antiepileptic drugs. In D. Janz, and H. H. Frey (ed.), Antiepileptic drugs. Handbook of Experimental Pharmacology, Springer, Berlin, 1984.
10. J. A. Cramer, R. H. Mattson, M. C. Prevey, R. D. Scheyer, and V. L. Ovellette. How often is medication taken as prescribed? A novel assessment technique. J Am Med Ass. 261:3273-3277 (1989).
11. P. J. W. McKee, J. BlackLaw, A. Carswell, R. A. Gillham, and M. J. Brodie. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients. Br J Clin Pharmacol. 36:257-261 (1993).
12. N. S. Barakat, and M. A. Radwan. In vitro performance of carbamazepine loaded to various molecular weights of poly (D,L-lactide-co-glycolide). Drug Delivery. 13:9-18 (2006).
13. N. S. Barakat, and A. B. Yassin. In vitro characterization of carbamazepine-loaded Precifac lipospheres. Drug Delivery. 13:95-104 (2006).
14. J. W. Moore, and H. H. Flanner. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharmaceut Technol. 20:64-74 (1996).
15. K. A. Khan. The concept of dissolution efficiency. J Pharm Pharmacol. 27:48-49 (1975).
16. D. Voegele, D. Brockmeier, H. M. Von Hattingberg, and B. C. Lippold. Die mittlere Auflösezeit-ein parameter zur prüfung von liberationsbedingungen auf vergleichbarkeit. Acta Pharm Techno. 29:167-174 (1985).
17. P. L. Ritger, and N. S. Peppas. A simple equation for disposition of solute release II: Fickian and anomalous release from swellable devices. J Control Rel. 5:37-42 (1987).
18. E. Gavini, A. B. Hegge, G. Rassu, V. Sanna, C. Testa, G. Pirisino, J. Karlsen, and P. Giunchedi. Nasal administration of Carbamazepine using chitosan microspheres: In vitro/in vivo studies. Int J Pharm. 307:9-15 (2006).
19. J. Wagner, and E. Nelson. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single dose of drug. J Pharm. Sci. 53:1392-1404 (1964).
20. I. Kushida, M. Ichikawa, and N. Asakawa. Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/ cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J Pharm Sci. 91:258-266 (2002).
21. I. Katzhendler, R. Azoury, and M. Friedman. Crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets based on hydroxypropyl methylcellulose. J Control Rel. 54:69-85 (1998).
22. C. Lefebvre, A. M. Guyot-Hermann, M. Draguet-Brighmans, R. Bouché, and J. C. Guyot. Polymorphic transitions of carbamazepine during grinding and compression. Drug Dev Ind Pharm. 12:1913-1927 (1986).
23. M. Otsuka, T. Ohfusa, and Y. Matsuda. Effect of binders on polymorphic transformation kinetics of carbamazepine in aqueous solution. Colloids and Surfaces B: Biointerfaces. 17:145-152 (2000).
24. S. Luhtala. Effect of sodium lauryl sulphate and polysorbate 80 on crystal growth and aqueous solubility of carbamazepine. Acta Pharm. Nord. 4:85-90 (1992).
25. Y. Qiu, H. S. Cheskin, K. R. Engh, and R. P. Poska. Once-a-day controlled-release dosage form of divalproex sodium I: Formulation design and in vitro/in vivo investigations. J Pharm Sci. 92:1166-1173 (2003).
26. J. B. Dressman, G. L. Amidon, C. Reppas, and V. P. Shah. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res. 15:11-22 (1998).
27. United States Pharmacopoeia 24/The National Formulary 21. USP Convention, Rockville, MD, 2000.
28. T. Mayer, T. W. May, D. -M. Altenmüller, M. Sandmann, and P. Wolf. Clinical problems with generic antiepileptic drugs: Comparison of sustained-release formulations of Carbamazepine. Clin Drug Invest. 18:17-26 (1999).